Preview: American College of Cardiology 2017

The 2017 American College of Cardiology (ACC) 66th Scientific Session & Expo will take place from Friday, March 17, through Sunday, March 19, in Washington, DC.

This year, the ACC accepted 23 late-breaking clinical trials, 17 of which were accepted as featured clinical research. Much of the research will be presented with simultaneous publication in either the Journal of the American College of Cardiology or the New England Journal of Medicine.

In a media telebriefing, ACC President Richard Chazal, MD, emphasized some nonclinical topics such as learning pathways and public reporting that will help improve care.

 

Read on for recommended highlights and be sure to follow Endocrinology Advisor’s coverage of ACC 2017.

ACC 2017 Clinical Trials and Featured Research Highlights

Friday, March 17

FOURIER: Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial

A long-term outcomes trial to be presented in the opening session. A total of 27,000 patients receiving statin therapy with myocardial infarction, peripheral artery disease, or stroke were included in this randomized, placebo, double-blind trial.

SPIRE 1 and SPIRE 2: Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High Risk Patients

When this trial was halted in November 2016, important end points had already been gathered. Patients in both SPIRE 1 and SPIRE 2 were receiving maximum tolerated doses of statins and were randomly assigned to receive bococizumab.

LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial

ORION 1 is a featured clinical research presentation that Dr Kuvin emphasized will be incredibly important for cholesterol management and prevention, despite it not being an outcomes study. The trial focused on low-density lipoprotein reduction using infrequent dosing. Some of these data have been presented in the past, but only very early outcomes.

Saturday, March 18

REACH: e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

This study examined the timing of anticoagulation therapy for venous thromboembolism (VTE). The primary end point was recurrent VTE plus cardiovascular events and safety end points, including bleeding.

Sunday, March 19

Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled STOMP: The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function

CVD-REAL Study: Lower Rates of Hospitalization for Heart Failure in New Users of SGLT-2 Inhibitors vs Other Glucose Lowering Drugs — Real-World Data From Four Countries and More Than 360,000 Patients

CVD-REAL is a comparative effectiveness study between new users of SGLT-2 inhibitors vs new users of other glucose lowering drugs. Data were collected from over 350,000 patients in 6 countries: the US, UK, Germany, Sweden, Denmark, and Norway; primary end point was hospitalization incidence for HF from index date up to 1 year.